Current Report Filing (8-k)
February 11 2016 - 4:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 5, 2016
DAVITA HEALTHCARE PARTNERS INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
1-14106 |
|
No. 51-0354549 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
2000 16th Street
Denver, CO 80202
(Address
of principal executive offices including Zip Code)
(303) 405-2100
(Registrants telephone number, including area code)
Not applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On February 5, 2016, DaVita Rx, LLC (Rx), a pharmacy
services provider and a wholly owned subsidiary of DaVita HealthCare Partners Inc. (the Company), received a Civil Investigative Demand (the CID) from the U.S. Attorneys Office for the Northern District of Texas. Based
on the language of the CID, the government is conducting a False Claims Act investigation concerning allegations that Rx presented or caused to be presented false claims for payment to the government for prescription medications. The CID covers the
period from January 1, 2006 through the present.
The Company maintains policies and procedures to promote compliance with the False
Claims Act and other applicable laws and regulations, and intends to cooperate with the government. The Company cannot predict, however, when this investigation will be resolved, its eventual outcome or scope, or its potential impact on the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
DAVITA HEALTHCARE PARTNERS INC. |
|
|
|
Date: February 11, 2016 |
|
|
|
/s/ Martha Ha |
|
|
|
|
Martha Ha |
|
|
|
|
Vice President, Corporate Secretary, and General Counsel Corporate & International |
DaVita (NYSE:DVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
DaVita (NYSE:DVA)
Historical Stock Chart
From Apr 2023 to Apr 2024